Phreesia Inc. (PHR) Acquires Insignia Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Phreesia Inc. (PHR) PT Lowered to $54 at Citi
December 10, 2021 6:37 AM ESTCiti analyst Daniel Grosslight lowered the price target on Phreesia Inc. (NYSE: PHR) to $54.00 (from $72.00) while maintaining a Neutral rating.... More
Pre-Open Stock Movers 12/09: (IINN) (AVCT) (RH) Higher; (RETA) (RLMD) (GME) Lower (more...)
December 9, 2021 9:29 AM ESTPre-Open Movers:
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) 113% HIGHER; signed an exclusive summary distribution agreement with Innovimed Sp. z o.o ("Innovimed"), a master distributor specializing in state-of-the-art medical solutions in Eastern Europe, Middle East and Africa. The Innovimed leadership team, have decades of experience with sales, marketing and distribution with medical devices in global healthcare industry companies including Baxter (AG).
Reata Pharmaceuticals, Inc. (Nasdaq:... More
Phreesia Inc. (PHR) PT Lowered to $65 at Needham & Company, But 'Buyers on Weakness'
December 9, 2021 7:07 AM ESTNeedham & Company analyst Ryan MacDonald lowered the price target on Phreesia Inc. (NYSE: PHR) to $65.00 (from $81.00) while maintaining a Buy rating.
The analyst commented, "We reiterate our Buy rating, while lowering our PT to $65, following the company's 3QF22 results in which revenue... More
Phreesia Inc. (PHR) PT Lowered to $51 at RBC Capital
December 9, 2021 7:01 AM ESTRBC Capital analyst Sean Dodge lowered the price target on Phreesia Inc. (NYSE: PHR) to $51.00 (from $60.00) while maintaining a Sector Perform rating.... More
